Covalon Technologies Ltd. (CVALF)
USD 2.42
(-1.63%)
USD 2.42
(-1.63%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 26.59 Million CAD | 46.56% |
| 2022 | 18.14 Million CAD | -7.23% |
| 2021 | 19.56 Million CAD | -24.18% |
| 2020 | 25.8 Million CAD | -24.13% |
| 2019 | 34 Million CAD | 27.25% |
| 2018 | 26.72 Million CAD | -2.15% |
| 2017 | 27.3 Million CAD | 306.94% |
| 2016 | 6.71 Million CAD | -11.57% |
| 2015 | 7.58 Million CAD | -16.25% |
| 2014 | 9.06 Million CAD | 119.18% |
| 2013 | 4.13 Million CAD | 8.98% |
| 2012 | 3.79 Million CAD | 46.58% |
| 2011 | 2.58 Million CAD | -19.9% |
| 2010 | 3.23 Million CAD | 41.37% |
| 2009 | 2.28 Million CAD | -7.58% |
| 2008 | 2.47 Million CAD | 92.35% |
| 2007 | 1.28 Million CAD | 36.95% |
| 2006 | 938.8 Thousand CAD | 0.0% |
| 2005 | - CAD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 9.22 Million CAD | 9.64% |
| 2024 Q1 | 4.66 Million CAD | -32.37% |
| 2024 Q2 | 8.41 Million CAD | 80.43% |
| 2023 Q2 | 7.24 Million CAD | 17.12% |
| 2023 Q4 | 6.89 Million CAD | 9.97% |
| 2023 Q3 | 6.27 Million CAD | -13.45% |
| 2023 FY | 26.59 Million CAD | 46.56% |
| 2023 Q1 | 6.18 Million CAD | 14.75% |
| 2022 Q3 | 4.52 Million CAD | 37.41% |
| 2022 Q4 | 5.39 Million CAD | 19.09% |
| 2022 Q2 | 3.29 Million CAD | -33.27% |
| 2022 Q1 | 4.93 Million CAD | 348.82% |
| 2022 FY | 18.14 Million CAD | -7.23% |
| 2021 Q2 | 6.74 Million CAD | 12.57% |
| 2021 Q1 | 5.98 Million CAD | 1.16% |
| 2021 Q3 | 8.81 Million CAD | 30.77% |
| 2021 FY | 19.56 Million CAD | -24.18% |
| 2021 Q4 | -1.98 Million CAD | -122.5% |
| 2020 Q4 | 5.91 Million CAD | -11.3% |
| 2020 FY | 25.8 Million CAD | -24.13% |
| 2020 Q2 | 5.25 Million CAD | -33.84% |
| 2020 Q1 | 7.94 Million CAD | 20.86% |
| 2020 Q3 | 6.67 Million CAD | 26.91% |
| 2019 Q3 | 6.85 Million CAD | -48.51% |
| 2019 Q2 | 13.31 Million CAD | 83.33% |
| 2019 Q1 | 7.26 Million CAD | 9.07% |
| 2019 FY | 34 Million CAD | 27.25% |
| 2019 Q4 | 6.57 Million CAD | -4.05% |
| 2018 Q1 | 6.4 Million CAD | -34.89% |
| 2018 Q2 | 5.72 Million CAD | -10.58% |
| 2018 Q3 | 7.93 Million CAD | 38.52% |
| 2018 Q4 | 6.65 Million CAD | -16.08% |
| 2018 FY | 26.72 Million CAD | -2.15% |
| 2017 Q2 | 6 Million CAD | 7.07% |
| 2017 Q3 | 5.9 Million CAD | -1.73% |
| 2017 Q4 | 9.83 Million CAD | 66.69% |
| 2017 FY | 27.3 Million CAD | 306.94% |
| 2017 Q1 | 5.6 Million CAD | 542.77% |
| 2016 Q3 | 2.6 Million CAD | 225.92% |
| 2016 Q2 | 797.74 Thousand CAD | -67.31% |
| 2016 Q1 | 2.44 Million CAD | 16.36% |
| 2016 FY | 6.71 Million CAD | -11.57% |
| 2016 Q4 | 872.62 Thousand CAD | -66.44% |
| 2015 Q2 | 2.18 Million CAD | 63.11% |
| 2015 Q4 | 2.09 Million CAD | 6.23% |
| 2015 FY | 7.58 Million CAD | -16.25% |
| 2015 Q3 | 1.97 Million CAD | -9.45% |
| 2015 Q1 | 1.33 Million CAD | 10.82% |
| 2014 Q2 | 2.04 Million CAD | -54.85% |
| 2014 Q4 | 1.2 Million CAD | -6.6% |
| 2014 Q1 | 4.52 Million CAD | 190.88% |
| 2014 FY | 9.06 Million CAD | 119.18% |
| 2014 Q3 | 1.29 Million CAD | -36.75% |
| 2013 FY | 4.13 Million CAD | 8.98% |
| 2013 Q4 | 1.55 Million CAD | 5.21% |
| 2013 Q3 | 1.47 Million CAD | 178.88% |
| 2013 Q2 | 529.85 Thousand CAD | -7.37% |
| 2013 Q1 | 572 Thousand CAD | -38.87% |
| 2012 Q1 | 689.16 Thousand CAD | 20.39% |
| 2012 FY | 3.79 Million CAD | 46.58% |
| 2012 Q4 | 935.68 Thousand CAD | -13.25% |
| 2012 Q3 | 1.07 Million CAD | -1.05% |
| 2012 Q2 | 1.09 Million CAD | 58.17% |
| 2011 Q2 | 1.01 Million CAD | 52.99% |
| 2011 FY | 2.58 Million CAD | -19.9% |
| 2011 Q1 | 661.11 Thousand CAD | 9.19% |
| 2011 Q4 | 572.42 Thousand CAD | 66.86% |
| 2011 Q3 | 343.04 Thousand CAD | -66.08% |
| 2010 Q1 | 794.67 Thousand CAD | 29.31% |
| 2010 FY | 3.23 Million CAD | 41.37% |
| 2010 Q4 | 605.47 Thousand CAD | -39.6% |
| 2010 Q3 | 1 Million CAD | 20.99% |
| 2010 Q2 | 828.52 Thousand CAD | 4.26% |
| 2009 FY | 2.28 Million CAD | -7.58% |
| 2009 Q4 | 614.54 Thousand CAD | 43.8% |
| 2009 Q3 | 427.37 Thousand CAD | -45.31% |
| 2009 Q2 | 781.43 Thousand CAD | 117.87% |
| 2009 Q1 | 358.67 Thousand CAD | -64.05% |
| 2008 Q2 | 308.41 Thousand CAD | -49.22% |
| 2008 Q3 | 337.26 Thousand CAD | 9.35% |
| 2008 FY | 2.47 Million CAD | 92.35% |
| 2008 Q4 | 997.73 Thousand CAD | 195.83% |
| 2008 Q1 | 607.33 Thousand CAD | 56.9% |
| 2007 Q1 | 337.76 Thousand CAD | 3.5% |
| 2007 Q3 | 203.42 Thousand CAD | -43.08% |
| 2007 Q4 | 387.08 Thousand CAD | 90.29% |
| 2007 Q2 | 357.4 Thousand CAD | 5.81% |
| 2007 FY | 1.28 Million CAD | 36.95% |
| 2006 FY | 938.8 Thousand CAD | 0.0% |
| 2006 Q3 | 351.22 Thousand CAD | 164.0% |
| 2006 Q2 | 133.04 Thousand CAD | -2.96% |
| 2006 Q1 | 137.09 Thousand CAD | 0.0% |
| 2006 Q4 | 326.34 Thousand CAD | -7.08% |
| 2005 Q3 | 41.31 Thousand CAD | 463.31% |
| 2005 Q2 | 7334.00 CAD | 225.96% |
| 2005 Q4 | - CAD | -100.0% |
| 2005 FY | - CAD | 0.0% |
| 2005 Q1 | 2250.00 CAD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.77 Million USD | -68.613% |
| Nanobac Pharmaceuticals, Incorporated | 17.62 Thousand USD | -150829.493% |
| SQZ Biotechnologies Company | 21.47 Million USD | -23.826% |
| Evofem Biosciences, Inc. | 18.21 Million USD | -45.984% |
| Santhera Pharmaceuticals Holding AG | 122.95 Million USD | 78.37% |
| Mesoblast Limited | 5.9 Million USD | -350.615% |
| Propanc Biopharma, Inc. | - USD | -Infinity% |
| Genus plc | 668.8 Million USD | 96.023% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -6384.046% |
| Marizyme, Inc. | 645.81 Thousand USD | -4018.129% |
| ContraFect Corporation | - USD | -Infinity% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -34546.873% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -40362.643% |
| AXIM Biotechnologies, Inc. | 39.51 Thousand USD | -67199.17% |
| MultiCell Technologies, Inc. | 49.32 USD | -53923837.551% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 49.72 Million USD | 46.511% |
| EV Biologics, Inc. | 48.9 Thousand USD | -54287.088% |
| Q BioMed Inc. | 284.35 Thousand USD | -9252.945% |
| Emmaus Life Sciences, Inc. | 29.59 Million USD | 10.142% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | - USD | -Infinity% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 245.31 Million USD | 89.159% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -37893.266% |
| Skye Bioscience, Inc. | - USD | -Infinity% |
| Therapeutic Solutions International, Inc. | 98.99 Thousand USD | -26765.553% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 75.72 Thousand USD | -35021.343% |
| IMV Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 658.5 Thousand USD | -3938.768% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | - USD | -Infinity% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 14.69 Billion USD | 99.819% |
| Halberd Corporation | 999.00 USD | -2662090.791% |
| Enzolytics Inc. | 52.79 Thousand USD | -50273.676% |
| Resverlogix Corp. | - USD | -Infinity% |
| Affymax, Inc. | 1.36 Million USD | -1842.68% |
| SYBLEU INC | 11.69 Thousand USD | -227287.876% |
| Nuo Therapeutics, Inc. | 608.52 Thousand USD | -4270.451% |
| argenx SE | 1.22 Billion USD | 97.831% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 1.93 Million USD | -1276.568% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -4207.738% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 839.52 Million USD | 96.832% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 145.09 Million USD | 81.671% |
| Provectus Biopharmaceuticals, Inc. | 557.71 Thousand USD | -4668.659% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 997.72 Thousand USD | -2565.59% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 48.35 Million USD | 44.999% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 16.68 Million USD | -59.393% |
| ONE Bio Corp. | 52.29 Million USD | 49.145% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -11142.512% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -11142.512% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 140.24 Thousand USD | -18863.852% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| CytoDyn Inc. | - USD | -Infinity% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 473.73 Thousand USD | -5514.018% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 7.78 Million USD | -241.447% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 13 Thousand USD | -204479.123% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | - USD | -Infinity% |
| Neutra Corp. | 39.53 Thousand USD | -67171.933% |
| Windtree Therapeutics, Inc. | - USD | -Infinity% |
| PureTech Health plc | 3.33 Million USD | -698.657% |
| Coeptis Therapeutics, Inc. | - USD | -Infinity% |
| IXICO plc | 6.66 Million USD | -299.029% |
| IntelGenx Technologies Corp. | 1.03 Million USD | -2459.7% |
| Gelesis Holdings, Inc. | 25.76 Million USD | -3.215% |
| CSL Limited | 14.8 Billion USD | 99.82% |
| Cellectis S.A. | 755 Thousand USD | -3422.554% |